{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:50:42Z","timestamp":1790819442059,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T00:00:00Z","timestamp":1471478400000},"content-version":"vor","delay-in-days":352,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejca.2015.06.117","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T07:44:41Z","timestamp":1436946281000},"page":"2008-2021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The potential of clofarabine in MLL -rearranged infant acute lymphoblastic leukaemia"],"prefix":"10.1016","volume":"51","author":[{"given":"Dominique J.P.M.","family":"Stumpel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9617","key":"10.1016\/j.ejca.2015.06.117_b0005","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.117_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11899-009-0023-4","article-title":"Infant acute lymphoblastic leukemia: lessons learned and future directions","volume":"4","author":"Pieters","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"issue":"9583","key":"10.1016\/j.ejca.2015.06.117_b0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.117_b0020","first-page":"372","article-title":"Infant leukaemia biology, aetiology and treatment","volume":"10","author":"Greaves","year":"1996","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.117_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.V96.1.24","article-title":"Biological and therapeutic aspects of infant leukemia","volume":"96","author":"Biondi","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2015.06.117_b0030","first-page":"762","article-title":"Biology and treatment of infant leukemias","volume":"9","author":"Pui","year":"1995","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ejca.2015.06.117_b0035","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.leu.2401129","article-title":"Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia\u2013implications for treatment of infants","volume":"12","author":"Pieters","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.117_b0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.leu.2403253","article-title":"In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype","volume":"18","author":"Ramakers-van Woerden","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejca.2015.06.117_b0045","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2002-05-1600","article-title":"Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia","volume":"101","author":"Stam","year":"2003","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.ejca.2015.06.117_b0050","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","article-title":"Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options","volume":"114","author":"Stumpel","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ejca.2015.06.117_b0055","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","article-title":"Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting","volume":"115","author":"Schafer","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ejca.2015.06.117_b0060","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/jnci\/dji311","article-title":"DNA methyltransferase inhibitors and the development of epigenetic cancer therapies","volume":"97","author":"Lyko","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ejca.2015.06.117_b0065","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2015.06.117_b0070","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2015.06.117_b0075","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2011.04.011","article-title":"Failure of hypomethylating agent-based therapy in myelodysplastic syndromes","volume":"38","author":"Kadia","year":"2011","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.117_b0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.2010.08213.x","article-title":"Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation","volume":"150","author":"Blum","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2015.06.117_b0085","first-page":"149","article-title":"Systematic in-vitro evaluation of the NCI\/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia","volume":"4","author":"Hoeksema","year":"2011","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.117_b0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0006-2952(02)01486-7","article-title":"The effects of cladribine and fludarabine on DNA methylation in K562 cells","volume":"65","author":"Wyczechowska","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.ejca.2015.06.117_b0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrd2055","article-title":"Discovery and development of clofarabine: a nucleoside analogue for treating cancer","volume":"5","author":"Bonate","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"723","key":"10.1016\/j.ejca.2015.06.117_b0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejphar.2013.11.021","article-title":"Clofarabine, a novel adenosine analogue, reactivates DNA methylation-silenced tumour suppressor genes and inhibits cell growth in breast cancer cells","volume":"15","author":"Lubecka-Pietruszewska","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2015.06.117_b0105","first-page":"4601","article-title":"Influence of clofarabine on transcriptional activity of PTEN, APC, RARB2, ZAP70 genes in K562 cells","volume":"30","author":"Majda","year":"2010","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2015.06.117_b0110","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2015.06.117_b0115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2141.2011.08752.x","article-title":"Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia","volume":"154","author":"O\u2019Connor","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.117_b0120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/pbc.24789","article-title":"Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia","volume":"61","author":"Shukla","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2015.06.117_b0125","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/bjc.1994.446","article-title":"Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay","volume":"70","author":"Kaspers","year":"1994","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.117_b0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.1994.tb04726.x","article-title":"The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7","volume":"86","author":"Greil","year":"1994","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.117_b0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V65.1.21.21","article-title":"Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics","volume":"65","author":"Stong","year":"1985","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2015.06.117_b0140","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V76.11.2327.2327","article-title":"In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions","volume":"76","author":"Pieters","year":"1990","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejca.2015.06.117_b0145","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1038\/nprot.2007.314","article-title":"DNA methylation analysis by pyrosequencing","volume":"2","author":"Tost","year":"2007","journal-title":"Nat Protoc"},{"issue":"14","key":"10.1016\/j.ejca.2015.06.117_b0150","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/blood-2009-07-233049","article-title":"Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants","volume":"115","author":"Stam","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.117_b0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.leu.2404074","article-title":"Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia","volume":"20","author":"Stam","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ejca.2015.06.117_b0160","first-page":"912","article-title":"The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells","volume":"91","author":"de Vries","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.117_b0165","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood.V90.1.346","article-title":"Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein","volume":"90","author":"Gati","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2015.06.117_b0170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-004-0906-y","article-title":"Biochemical modulation of cytarabine triphosphate by clofarabine","volume":"55","author":"Cooper","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2015.06.117_b0175","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood"},{"issue":"5\u20137","key":"10.1016\/j.ejca.2015.06.117_b0180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1081\/NCN-200059765","article-title":"Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology","volume":"24","author":"Marquez","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"4","key":"10.1016\/j.ejca.2015.06.117_b0185","first-page":"1657","article-title":"Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro","volume":"34","author":"Yamauchi","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.117_b0190","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MPH.0b013e31820fee1d","article-title":"Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia","volume":"34","author":"Moreno","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.117_b0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MOH.0000000000000123","article-title":"Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L","volume":"22","author":"Stein","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.117_b0200","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.114.214577","article-title":"DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells","volume":"350","author":"Klaus","year":"2014","journal-title":"J Pharmacol Exp Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915006437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915006437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:09:40Z","timestamp":1717978180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915006437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":40,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0959804915006437"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.06.117","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.06.117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}